Metraipolis › archive › dc_0abc7c70ef4c

Chimeric antigen receptor macrophages therapy for glioblastoma: challenges and opportunities from preclinical evidence to clinical translation — Europe PMC PMID:41737231

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41737231
DOI
10.3389/fimmu.2026.1726329
License (as archived)
solo-consultazione
Archived
2026-11-06T00:14:31.642Z
SHA-256 of the archived text
42b9b03f8f059f1bbc28fb8a381171d2096913fed24dcc90acb054cd19db81e6
Stable URL of this page
https://metraipolis.com/documento/dc_0abc7c70ef4c

How to cite

Chimeric antigen receptor macrophages therapy for glioblastoma: challenges and opportunities from preclinical evidence to clinical translation — Europe PMC PMID:41737231 — Europe PMC (en), https://europepmc.org/article/MED/41737231 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0abc7c70ef4c (Metraipolis archive dc_0abc7c70ef4c, sha256 42b9b03f8f059f1bbc28fb8a381171d2096913fed24dcc90acb054cd19db81e6)
BibTeX
@misc{dc0abc7c70ef4c,
  title = {Chimeric antigen receptor macrophages therapy for glioblastoma: challenges and opportunities from preclinical evidence to clinical translation — Europe PMC PMID:41737231},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41737231},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0abc7c70ef4c; sha256 42b9b03f8f059f1bbc28fb8a381171d2096913fed24dcc90acb054cd19db81e6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41737231. Agents can read the archived copy with the MCP tool read_document.